MERCK'S ZOCOR PREFERRED BY 35% OF PHYSICIANS FOR PATIENTS WITH CHD, NHLBI CHOLESTEROL SURVEY FINDS; 5% OF U.S. TAKING CHOLESTEROL-LOWERING DRUG THERAPY
Merck's Zocor is "preferred" by 35% of physicians for cholesterol-lowering in patients with coronary heart disease, according to the 1995 Cholesterol Awareness Survey conducted by the National Heart, Lung & Blood Institute.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth